| Mrs Cherity Dawn Burrows, APRN-CNP | |
|
916 N Main St, Altus, OK 73521-3118 | |
| (580) 480-0033 | |
| Not Available |
| Full Name | Mrs Cherity Dawn Burrows |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 916 N Main St, Altus, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285977801 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 92233 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jackson County Memorial Hospital Authority | Altus, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Altus Premier Health Clinic Pllc | 9335448752 | 4 |
News Archive
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
A team of scientists from Canada, Thailand and Morocco have found that DHEA-S may prevent neurocognitive impairment that affects a significant percentage of AIDS patients. In a report appearing in the February 2013 issue of The FASEB Journal, they describe how a network of steroid molecules found in the brain, termed "neurosteroids," is disrupted during HIV infection leading to brain damage.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
In celebration of National Senior Citizens Day, this Friday, August 21(st), the National PACE Association is working with many of the individual Programs of All-inclusive Care for the Elderly (PACE) around the country to educate their surrounding communities about PACE through health fairs and open houses.
Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).
› Verified 9 days ago
| Entity Name | A Plus Minor Emergency Walk In Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740615426 PECOS PAC ID: 3870724289 Enrollment ID: O20140328000654 |
News Archive
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
A team of scientists from Canada, Thailand and Morocco have found that DHEA-S may prevent neurocognitive impairment that affects a significant percentage of AIDS patients. In a report appearing in the February 2013 issue of The FASEB Journal, they describe how a network of steroid molecules found in the brain, termed "neurosteroids," is disrupted during HIV infection leading to brain damage.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
In celebration of National Senior Citizens Day, this Friday, August 21(st), the National PACE Association is working with many of the individual Programs of All-inclusive Care for the Elderly (PACE) around the country to educate their surrounding communities about PACE through health fairs and open houses.
Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).
› Verified 9 days ago
| Entity Name | Altus Premier Health Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528408523 PECOS PAC ID: 9335448752 Enrollment ID: O20160505001401 |
News Archive
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
A team of scientists from Canada, Thailand and Morocco have found that DHEA-S may prevent neurocognitive impairment that affects a significant percentage of AIDS patients. In a report appearing in the February 2013 issue of The FASEB Journal, they describe how a network of steroid molecules found in the brain, termed "neurosteroids," is disrupted during HIV infection leading to brain damage.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
In celebration of National Senior Citizens Day, this Friday, August 21(st), the National PACE Association is working with many of the individual Programs of All-inclusive Care for the Elderly (PACE) around the country to educate their surrounding communities about PACE through health fairs and open houses.
Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Cherity Dawn Burrows, APRN-CNP 916 N Main St, Altus, OK 73521-3118 Ph: (580) 480-0033 | Mrs Cherity Dawn Burrows, APRN-CNP 916 N Main St, Altus, OK 73521-3118 Ph: (580) 480-0033 |
News Archive
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
A team of scientists from Canada, Thailand and Morocco have found that DHEA-S may prevent neurocognitive impairment that affects a significant percentage of AIDS patients. In a report appearing in the February 2013 issue of The FASEB Journal, they describe how a network of steroid molecules found in the brain, termed "neurosteroids," is disrupted during HIV infection leading to brain damage.
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
In celebration of National Senior Citizens Day, this Friday, August 21(st), the National PACE Association is working with many of the individual Programs of All-inclusive Care for the Elderly (PACE) around the country to educate their surrounding communities about PACE through health fairs and open houses.
Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).
› Verified 9 days ago
Jonie Gene Lyon, APRN, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 416 N Main St, Altus, OK 73521 Phone: 580-379-0925 | |
Brita Marie Angelone, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 580-379-5690 | |
Alexis Bielski, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 101 S Park Ln Ste 100, Altus, OK 73521 Phone: 580-379-6100 Fax: 580-379-6109 | |
Tiffany J Forster, APRN-CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3000 N Main St Ste A, Altus, OK 73521 Phone: 580-563-0454 Fax: 580-603-8602 | |
Jana Finch, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 401 W Tamarack Rd, Altus, OK 73521 Phone: 609-495-4115 | |
Mrs. Kristi Nicole Fry, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 205 S Park Ln, Altus, OK 73521 Phone: 580-379-6650 Fax: 580-379-6659 |